According to Zhitong Finance App News, Kehua Biotech (002022.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 838 million yuan, an increase of 5.54% over the previous year; net loss attributable to shareholders of listed companies of 104 million yuan; net loss of 114 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss; and basic earnings per share -0.2017 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.